Jennison Associates LLC Arcutis Biotherapeutics, Inc. Transaction History
Jennison Associates LLC
- $155 Billion
- Q2 2024
A detailed history of Jennison Associates LLC transactions in Arcutis Biotherapeutics, Inc. stock. As of the latest transaction made, Jennison Associates LLC holds 11,571,694 shares of ARQT stock, worth $100 Million. This represents 0.07% of its overall portfolio holdings.
Number of Shares
11,571,694
Previous 12,176,315
4.97%
Holding current value
$100 Million
Previous $121 Million
10.82%
% of portfolio
0.07%
Previous 0.08%
Shares
9 transactions
Others Institutions Holding ARQT
# of Institutions
193Shares Held
128MCall Options Held
5.43MPut Options Held
257K-
Suvretta Capital Management, LLC New York, NY10MShares$86.7 Million3.89% of portfolio
-
Rubric Capital Management LP New York, NY9.82MShares$85.1 Million2.7% of portfolio
-
Frazier Life Sciences Management, L.P. Menlo Park, CA8.79MShares$76.2 Million4.82% of portfolio
-
Black Rock Inc. New York, NY8.62MShares$74.8 Million0.0% of portfolio
-
Polar Capital Holdings PLC London, X06.88MShares$59.6 Million0.39% of portfolio
About Arcutis Biotherapeutics, Inc.
- Ticker ARQT
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 60,187,500
- Market Cap $522M
- Description
- Arcutis Biotherapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing treatments for dermatological diseases. Its lead product candidate is ARQ-151, a topical roflumilast cream that has completed Phase III clinical trials for the treatment of plaque psoriasis and atopic dermatitis. The company is also developing A...